Lupin gains on entering into agreement to market new inhaler under the brand name Loftair in India

12 Apr 2016 Evaluate

Lupin is currently trading at Rs. 1534.50, up by 17.00 points or 1.12% from its previous closing of Rs. 1517.50 on the BSE.

The scrip opened at Rs. 1528.00 and has touched a high and low of Rs. 1543.95 and Rs. 1528.00 respectively. So far 21,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1553.20 and Rs. 1466.50 respectively. The current market cap of the company is Rs. 69,141.00 crore.

The promoters holding in the company stood at 46.53% while Institutions and Non-Institutions held 43.56% and 9.92% respectively.

Pharma Major Lupin and Novartis Healthcare (NHPL) have entered into a co-marketing agreement to promote Novartis’ Indacaterol / Glycopyrronium 110mcg/50mcg inhaler, a treatment for chronic obstructive pulmonary disease (COPD) under the brand name of Loftair. Lupin would be using its own specialty field force to promote Loftair inhaler. NHPL will continue to market Indacaterol / Glycopyrronium 110mcg/50mcg inhaler under its brand name Sequadra through its own sales force.

Loftair is a fixed dose combination of two bronchodilators: Indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA) for the treatment of COPD. The once daily Indacaterol / Glycopyrronium combination significantly reduced the rate of moderate or severe exacerbations by 31% compared to the current standard of care (SFC twice-daily salmeterol + fluticasone combination) in patients with moderate-to-severe chronic obstructive pulmonary disease.

This combination has also shown superior efficacy vs SFC (salmeterol/fluticasone) for lung function, breathlessness (assessed using the Transition Dyspnea Index), health-related quality of life (measured using the St George’s Respiratory Questionnaire) and on-demand (rescue medication) salbutamol use. Indacaterol / Glycopyrronium combination is approved for use in COPD in 82 countries including US, EU, Japan, Canada, countries within Latin America and Australia. The agreement helps address the growing incidence of COPD, by making better treatment options available to patients in India. 


Lupin Share Price

2178.20 1.95 (0.09%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×